|
1
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwab M, Westermann F, Hero B and
Berthold F: Neuroblastoma: biology and molecular and chromosomal
pathology. Lancet Oncol. 4:472–480. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Canete A, Gerrard M, Rubie H, et al: Poor
survival for infants with MYCN-amplified metastatic neuroblastoma
despite intensified treatment: the International Society of
Paediatric Oncology European Neuroblastoma Experience. J Clin
Oncol. 27:1014–1019. 2009. View Article : Google Scholar
|
|
6
|
De Bernardi B, Gerrard M, Boni L, et al:
Excellent outcome with reduced treatment for infants with
disseminated neuroblastoma without MYCN gene amplification. J Clin
Oncol. 27:1034–1040. 2009.PubMed/NCBI
|
|
7
|
Johnsen JI, Segerstrom L, Orrego A, et al:
Inhibitors of mammalian target of rapamycin downregulate MYCN
protein expression and inhibit neuroblastoma growth in vitro and in
vivo. Oncogene. 27:2910–2922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Otto T, Horn S, Brockmann M, et al:
Stabilization of N-Myc is a critical function of Aurora A in human
neuroblastoma. Cancer Cell. 15:67–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ushmorov A, Hogarty MD, Liu X, Knauss H,
Debatin KM and Beltinger C: N-myc augments death and attenuates
protective effects of Bcl-2 in trophically stressed neuroblastoma
cells. Oncogene. 27:3424–3434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wallick CJ, Gamper I, Thorne M, et al: Key
role for p27Kip1, retinoblastoma protein Rb, and MYCN in
polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified
human neuroblastoma cells. Oncogene. 24:5606–5618. 2005.PubMed/NCBI
|
|
11
|
Koomoa DL, Yco LP, Borsics T, Wallick CJ
and Bachmann AS: Ornithine decarboxylase inhibition by
alpha-difluoromethylornithine activates opposing signaling pathways
via phosphorylation of both Akt/protein kinase B and
p27Kip1 in neuroblastoma. Cancer Res. 68:9825–9831.
2008. View Article : Google Scholar
|
|
12
|
Chiarle R, Pagano M and Inghirami G: The
cyclin dependent kinase inhibitor p27 and its prognostic role in
breast cancer. Breast Cancer Res. 3:91–94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chu IM, Hengst L and Slingerland JM: The
Cdk inhibitor p27 in human cancer: prognostic potential and
relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esposito V, Baldi A, De Luca A, et al:
Prognostic role of the cyclin-dependent kinase inhibitor p27 in
non-small cell lung cancer. Cancer Res. 57:3381–3385.
1997.PubMed/NCBI
|
|
15
|
Lee J and Kim SS: The function of
p27Kip1 during tumor development. Exp Mol Med.
41:765–771. 2009.
|
|
16
|
Ravanko K, Jarvinen K, Paasinen-Sohns A
and Holtta E: Loss of p27Kip1 from cyclin
E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4
complexes in cells transformed by polyamine biosynthetic enzymes.
Cancer Res. 60:5244–5253. 2000.PubMed/NCBI
|
|
17
|
Baldassarre G, Belletti B, Nicoloso MS, et
al: p27(Kip1)-stathmin interaction influences sarcoma cell
migration and invasion. Cancer Cell. 7:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itoh Y, Masuyama N, Nakayama K, Nakayama
KI and Gotoh Y: The cyclin-dependent kinase inhibitors p57 and p27
regulate neuronal migration in the developing mouse neocortex. J
Biol Chem. 282:390–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Z, Jiao X, Wang C, et al: Cyclin D1
induction of cellular migration requires p27(Kip1).
Cancer Res. 66:9986–9994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McAllister SS, Becker-Hapak M, Pintucci G,
Pagano M and Dowdy SF: Novel p27(Kip1) C-terminal
scatter domain mediates Rac-dependent cell migration independent of
cell cycle arrest functions. Mol Cell Biol. 23:216–228. 2003.
|
|
21
|
See WL, Heinberg AR, Holland EC and Resh
MD: p27 deficiency is associated with migration defects in
PDGF-expressing gliomas in vivo. Cell Cycle. 9:1562–1567. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stehr W, Mercer TI, Bernal NP, Erwin CR
and Warner BW: Opposing roles for p21(waf1/cip1) and
p27(Kip1) in enterocyte differentiation, proliferation,
and migration. Surgery. 138:187–194. 2005.PubMed/NCBI
|
|
23
|
Sun J, Marx SO, Chen HJ, Poon M, Marks AR
and Rabbani LE: Role for p27(Kip1) in vascular smooth muscle cell
migration. Circulation. 103:2967–2972. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Woods TC: Regulation of cell migration by
mTOR is mediated through changes in p27(Kip1) phosphorylation. Cell
Cycle. 9:2057–2058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Assoian RK: Stopping and going with
p27Kip1. Dev Cell. 6:458–459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Besson A, Gurian-West M, Schmidt A, Hall A
and Roberts JM: p27Kip1 modulates cell migration through
the regulation of RhoA activation. Genes Dev. 18:862–876. 2004.
|
|
27
|
Larrea MD, Wander SA and Slingerland JM:
p27 as Jekyll and Hyde: regulation of cell cycle and cell motility.
Cell Cycle. 8:3455–3461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iancu-Rubin C and Atweh GF:
p27(Kip1) and stathmin share the stage for the first
time. Trends Cell Biol. 15:346–348. 2005.
|
|
29
|
Denicourt C, Saenz CC, Datnow B, Cui XS
and Dowdy SF: Relocalized p27Kip1 tumor suppressor
functions as a cytoplasmic metastatic oncogene in melanoma. Cancer
Res. 67:9238–9243. 2007.PubMed/NCBI
|
|
30
|
Kossatz U, Vervoorts J, Nickeleit I, et
al: C-terminal phosphorylation controls the stability and function
of p27Kip1. EMBO J. 25:5159–5170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sicinski P, Zacharek S and Kim C: Duality
of p27Kip1 function in tumorigenesis. Genes Dev.
21:1703–1706. 2007. View Article : Google Scholar
|
|
32
|
Supriatno, Harada K, Kawaguchi S, Yoshida
H and Sato M: Effect of p27Kip1 on the ability of
invasion and metastasis of an oral cancer cell line. Oncol Rep.
10:527–532. 2003.
|
|
33
|
Wang XQ, Lui EL, Cai Q, et al:
p27Kip1 promotes migration of metastatic hepatocellular
carcinoma cells. Tumour Biol. 29:217–223. 2008.
|
|
34
|
Geerts D, Koster J, Albert D, et al: The
polyamine metabolism genes ornithine decarboxylase and antizyme 2
predict aggressive behavior in neuroblastomas with and without MYCN
amplification. Int J Cancer. 126:2012–2024. 2010.
|
|
35
|
Koomoa DL, Borsics T, Feith DJ, et al:
Inhibition of S-adenosylmethionine decarboxylase by inhibitor
SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein
kinase B regulation and apoptosis in neuroblastoma. Mol Cancer
Ther. 8:2067–2075. 2009. View Article : Google Scholar
|
|
36
|
Revet I, Huizenga G, Chan A, et al: The
MSX1 homeobox transcription factor is a downstream target of PHOX2B
and activates the Delta-Notch pathway in neuroblastoma. Exp Cell
Res. 314:707–719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Motti ML, Califano D, Troncone G, et al:
Complex regulation of the cyclin-dependent kinase inhibitor
p27Kip1 in thyroid cancer cells by the PI3K/AKT pathway:
regulation of p27Kip1 expression and localization. Am J
Pathol. 166:737–749. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Motti ML, De Marco C, Califano D, Fusco A
and Viglietto G: Akt-dependent T198 phosphorylation of
cyclin-dependent kinase inhibitor p27Kip1 in breast
cancer. Cell Cycle. 3:1074–1080. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
van Weeren PC, de Bruyn KM, de Vries-Smits
AM, van Lint J and Burgering BM: Essential role for protein kinase
B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation.
Characterization of dominant-negative mutant of PKB. J Biol Chem.
273:13150–13156. 1998.PubMed/NCBI
|
|
40
|
Bergmann E, Wanzel M, Weber A, Shin I,
Christiansen H and Eilers M: Expression of P27(Kip1) is
prognostic and independent of MYCN amplification in human
neuroblastoma. Int J Cancer. 95:176–183. 2001.
|
|
41
|
Borriello A, Bencivenga D, Criscuolo M, et
al: Targeting p27(Kip1) protein: its relevance in the
therapy of human cancer. Expert Opin Ther Targets. 15:677–693.
2011.
|
|
42
|
Richert MM, Phadke PA, Matters G, et al:
Metastasis of hormone-independent breast cancer to lung and bone is
decreased by alpha-difluoromethylornithine treatment. Breast Cancer
Res. 7:R819–R827. 2005. View Article : Google Scholar
|
|
43
|
Manni A, Washington S, Craig L, et al:
Effects of alpha-difluoromethylornithine on local recurrence and
pulmonary metastasis from MDA-MB-435 breast cancer xenografts in
nude mice. Clin Exp Metastasis. 20:321–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jun JY, Griffith JW, Bruggeman R, et al:
Effects of polyamine depletion by alpha-difluoromethylornithine on
in vitro and in vivo biological properties of 4T1 murine mammary
cancer cells. Breast Cancer Res Treat. 105:29–36. 2007. View Article : Google Scholar
|
|
45
|
Ohmori T, Okada K, Tabei R and Shibata T:
Effects on tumor induction, growth, metastasis and histology of
concurrent administration of putrescine and its metabolizing
inhibitor alpha-difluoromethylornithine in nickel tumorigenesis in
soft tissue. Carcinogenesis. 15:647–652. 1994. View Article : Google Scholar
|
|
46
|
Zirvi KA, Dasmahapatra KS, Atabek U and
Lyons MA: alpha-Difluoromethylornithine inhibits liver metastasis
produced by intrasplenic injection of human tumor cells into nude
mice. Clin Exp Metastasis. 7:591–598. 1989. View Article : Google Scholar
|
|
47
|
Kubota S, Ohsawa N and Takaku F: Effects
of DL-alpha-difluoromethylornithine on the growth and metastasis of
B16 melanoma in vivo. Int J Cancer. 39:244–247. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sunkara PS and Rosenberger AL:
Antimetastatic activity of DL-alpha-difluoromethylornithine, an
inhibitor of polyamine biosynthesis, in mice. Cancer Res.
47:933–935. 1987.PubMed/NCBI
|
|
49
|
Meyskens FL, Kingsley EM, Glattke T,
Loescher L and Booth A: A phase II study of
alpha-difluoromethylornithine (DFMO) for the treatment of
metastatic melanoma. Invest New Drugs. 4:257–262. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Klein S, Miret JJ, Algranati ID and de
Lustig ES: Effect of alpha-difluoromethylornithine in lung
metastases before and after surgery of primary adenocarcinoma
tumors in mice. Biol Cell. 53:33–36. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yaari S, Jacob-Hirsch J, Amariglio N,
Haklai R, Rechavi G and Kloog Y: Disruption of cooperation between
Ras and MycN in human neuroblastoma cells promotes growth arrest.
Clin Cancer Res. 11:4321–4330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hogarty MD, Norris MD, Davis K, et al:
ODC1 is a critical determinant of MYCN oncogenesis and a
therapeutic target in neuroblastoma. Cancer Res. 68:9735–9745.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rounbehler RJ, Li W, Hall MA, Yang C,
Fallahi M and Cleveland JL: Targeting ornithine decarboxylase
impairs development of MYCN-amplified neuroblastoma. Cancer Res.
69:547–553. 2009. View Article : Google Scholar : PubMed/NCBI
|
